Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

New 1,3,4‒oxadiazole Quinazolines as Potential Anticancer Agents: Design, Synthesis, Biological Evaluation, and In silico Studies

Author(s): Venkanna Gujja*, Kumaraswamy Sadineni, Shiva Kumar Koppula*, Avanthi Basireddy, Banothu Venkanna and Shravan Kumar Gunda

Volume 22, Issue 1, 2025

Published on: 09 April, 2024

Article ID: e090424228867 Pages: 13

DOI: 10.2174/0115701638282655240402042126

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

Background: A novel series of 1,3,4‒oxadiazole connected to derivatives of quinazolinone (7a–e and 8a–f) was synthesized in the current investigation, and its anticancer and Topoisomerase‒ II inhibitory activity was evaluated.

Objective: These findings inspired the design, synthesis, and biological analysis of these 1,3,4‒oxadiazole-quinazolinone analogues as antiproliferative Topo‒II inhibitors.

Methods: The novel compound structures were determined using mass spectrometry and spectral methods (IR, NMR: 1H & 13C). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide colourimetric assay has been used to evaluate the anticancer efficacy of these drugs, and Autodock 4.2 provides a description of the docking results. For the more active members, additional biological tests, such as the Topo‒II inhibition experiment, were performed. These compounds' physicochemical and ADMET characteristics were examined in more detail.

Results: In the experiment for antiproliferative activity, compounds 7d, 7e, 8c, 8e, and 8f demonstrated encouraging cytotoxicity findings against HCT‒116 and HepG2 cancer cell lines, with IC50 values ranging from 3.85 to 19.43 μM. Compounds 7d, 7e, and 8e were the most potent inhibitors of Topo II with IC50 values of 15.18, 17.55, and 12.59 μM, respectively. Additionally, the docked compound 8c showed the strongest conventional hydrogen bonds among the residues Leu507(B), Asn508(B), Asn520(B), and Glu522(B) in the Human topoisomerase‒IIβ active site in the DNA complex (4G0U) when compared to the findings of docking experiments.

Conclusion: New findings have discovered the fact that fused 1,3,4‒oxadiazole bearing quinazolinone contributed great significance in the field of medicinal chemistry due to their diverse biological properties. Finally, the in silico pharmacokinetic profile of all the synthesized derivatives was estimated using SwissADME, where some of the compounds followed Lipinski, Veber, Egan, and Muegge rules without deviation. The result of this activity advises that with a simple modification in structure, a potent anticancer agent can be generated with good efficacy.

Keywords: 1, 3, 4‒Oxadiazole, 2-amino-3-methylbenzoic acid, formamide, antiproliferative activity, topo II inhibitors, ADMET.

Graphical Abstract

[1]
Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009; 9(5): 338-50.
[http://dx.doi.org/10.1038/nrc2607] [PMID: 19377506]
[2]
Rescifina A, Zagni C, Varrica MG, Pistarà V, Corsaro A. Recent advances in small organic molecules as DNA intercalating agents: Synthesis, activity, and modeling. Eur J Med Chem 2014; 74: 95-115.
[http://dx.doi.org/10.1016/j.ejmech.2013.11.029] [PMID: 24448420]
[3]
Godzieba M, Ciesielski S. Natural DNA intercalators as promising therapeutics for cancer and Infectious diseases. Curr Cancer Drug Targets 2020; 20(1): 19-32.
[http://dx.doi.org/10.2174/1568009619666191007112516] [PMID: 31589125]
[4]
Yokochi T, Robertson KD. Doxorubicin inhibits DNMT1, resulting in conditional apoptosis. Mol Pharmacol 2004; 66(6): 1415-20.
[http://dx.doi.org/10.1124/mol.104.002634] [PMID: 15340041]
[5]
Ferguson LR, Denny WA. Genotoxicity of non-covalent interactions: DNA intercalators. Mutat Res 2007; 623(1-2): 14-23.
[http://dx.doi.org/10.1016/j.mrfmmm.2007.03.014] [PMID: 17498749]
[6]
Wang JC. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol 2002; 3(6): 430-40.
[http://dx.doi.org/10.1038/nrm831] [PMID: 12042765]
[7]
Shenkenberg TD, Von Hoff DD. Mitoxantrone: A new anticancer drug with significant clinical activity. Ann Intern Med 1986; 105(1): 67-81.
[http://dx.doi.org/10.7326/0003-4819-105-1-67] [PMID: 3521429]
[8]
Chilin A, Marzaro G, Marzano C, et al. Synthesis and antitumor activity of novel amsacrine analogs: The critical role of the acridine moiety in determining their biological activity. Bioorg Med Chem 2009; 17(2): 523-9.
[http://dx.doi.org/10.1016/j.bmc.2008.11.072] [PMID: 19101158]
[9]
Pujar GV, Moshin AS. Design, synthesis, and cytotoxicity evaluation of new 2,4-disubstituted quinazolines as potential anticancer agents. J Appl Pharm Sci 2020; 10(8): 37-42.
[10]
Altamimi AS, El-Azab AS, Abdelhamid SG, et al. Synthesis, anticancer screening of some novel trimethoxy quinazolines and VEGFR2, EGFR tyrosine kinase inhibitors assay; molecular docking studies. Molecules 2021; 26(10): 2992.
[http://dx.doi.org/10.3390/molecules26102992] [PMID: 34069962]
[11]
Jain N, Pandey VK. An efficient synthesis of tetrazolo indolo quinazolines and their antiviral study. J Chemist Chem Sci 2018; 8(4): 693-8.
[http://dx.doi.org/10.29055/jccs/628]
[12]
Wan Z, Hu D, Li P, Xie D, Gan X. Synthesis, Antiviral bioactivity of novel 4-thioquinazoline derivatives containing chalcone moiety. Molecules 2015; 20(7): 11861-74.
[http://dx.doi.org/10.3390/molecules200711861] [PMID: 26132908]
[13]
Lam T, Hilgers MT, Cunningham ML, et al. Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines. J Med Chem 2014; 57(3): 651-68.
[http://dx.doi.org/10.1021/jm401204g] [PMID: 24428639]
[14]
Jiang X, Yang S, Yan Y, et al. Design, synthesis, and insecticidal activity of 5,5-disubstituted 4,5-dihydropyrazolo [1,5-a]quinazolines as novel antagonists of GABA receptors. J Agric Food Chem 2020; 68(50): 15005-14.
[http://dx.doi.org/10.1021/acs.jafc.0c02462] [PMID: 33269911]
[15]
Nasrullayev AO, Tosheva NA, Elmuradov BZ, Eshmuratova AA, Azimova SS. Synthesis and in vitro investigation of insecticidal activity of some tricyclic quinazolines and their thioanalogues. J Basic appl Res 2016; 2(4): 470-5.
[16]
Alafeefy AM, Kadi AA, Deeb AOA, Tahir EKEH, jaber ANA. Synthesis, analgesic and anti-inflammatory evaluation of some novel quinazoline derivatives. Eur J Med Chem 2010; 45(11): 4947-52.
[http://dx.doi.org/10.1016/j.ejmech.2010.07.067] [PMID: 20817329]
[17]
Krasovska N, Stavytskyi V, Nosulenko I, Karpenko O, Voskoboinik O, Kovalenko S. Quinazoline-containing hydrazydes of dicarboxylic acids and products of their structural modification: A novel class of anti-inflammatory agents. Acta Chim Slov 2021; 68(2): 395-403.
[http://dx.doi.org/10.17344/acsi.2020.6440] [PMID: 34738126]
[18]
Alagarsamy V, Chitra K, Saravanan G, Solomon VR, Sulthana MT, Narendhar B. An overview of quinazolines: Pharmacological significance and recent developments. Eur J Med Chem 2018; 151: 628-85.
[http://dx.doi.org/10.1016/j.ejmech.2018.03.076] [PMID: 29656203]
[19]
Palaska E, Şahin G, Kelicen P, Durlu NT, Altinok G. Synthesis and anti-inflammatory activity of 1-acylthiosemicarbazides, 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazole-3-thiones. Farmaco 2002; 57(2): 101-7.
[http://dx.doi.org/10.1016/S0014-827X(01)01176-4] [PMID: 12164209]
[20]
Ahsan MJ, Samy JG, Khalilullah H, et al. Molecular properties prediction and synthesis of novel 1,3,4-oxadiazole analogues as potent antimicrobial and antitubercular agents. Bioorg Med Chem Lett 2011; 21(24): 7246-50.
[http://dx.doi.org/10.1016/j.bmcl.2011.10.057] [PMID: 22071303]
[21]
Rai LKM, Linganna N. Synthesis and evaluation of antimitotic activity of alkylated 2-amino-1,3,4-oxadiazole derivatives. Farmaco 2000; 55(5): 389-92.
[http://dx.doi.org/10.1016/S0014-827X(00)00056-2] [PMID: 10983285]
[22]
Joshi SD, Vagdevi HM, Vaidya VP, Gadaginamath GS. Synthesis of new 4-pyrrol-1-yl benzoic acid hydrazide analogs and some derived oxadiazole, triazole and pyrrole ring systems: A novel class of potential antibacterial and antitubercular agents. Eur J Med Chem 2008; 43(9): 1989-96.
[http://dx.doi.org/10.1016/j.ejmech.2007.11.016] [PMID: 18207286]
[23]
Kotaiah Y, Harikrishna N, Nagaraju K, Rao VC. Synthesis and antioxidant activity of 1,3,4-oxadiazole tagged thieno[2,3-d]pyrimidine derivatives. Eur J Med Chem 2012; 58: 340-5.
[http://dx.doi.org/10.1016/j.ejmech.2012.10.007] [PMID: 23149297]
[24]
Maddi V, Ingale N, Palkar M, Ronad P, Mamledesai S, Vishwanathswamy AHM. Synthesis and evaluation of anti-inflammatory and analgesic activity of 3-[(5-substituted-1,3,4-oxadiazol-2-yl-thio)acetyl]-2H-chromen-2-ones. Med Chem Res 2012; 21: 16-26.
[http://dx.doi.org/10.1007/s00044-010-9494-z]
[25]
Bondock S, Adel S, Etman HA, Badria FA. Synthesis and antitumor evaluation of some new 1,3,4-oxadiazole-based heterocycles. Eur J Med Chem 2012; 48: 192-9.
[http://dx.doi.org/10.1016/j.ejmech.2011.12.013] [PMID: 22204901]
[26]
Tutone M, Pecoraro B, Almerico AM. Investigation on quantitative structure-activity relationships of 1,3,4-oxadiazole derivatives as potential telomerase inhibitors. Curr Drug Discov Technol 2020; 17(1): 79-86.
[http://dx.doi.org/10.2174/1570163815666180724113208] [PMID: 30039762]
[27]
Naghibi H, Salari R, Yousefi M, Rezaiyan KM, Ghanbarzadeh MR, Bordbar FMR. Herbal therapies for weight gain and metabolic abnormalities induced by atypical antipsychotics: A review article. Curr Drug Discov Technol 2023; 20(5): e110423215660.
[http://dx.doi.org/10.2174/1570163820666230411111343] [PMID: 37055899]
[28]
Biernacki K, Daśko M, Ciupak O, Kubiński K, Rachon J, Demkowicz S. Novel 1,2,4-oxadiazole derivatives in drug discovery. Pharmaceuticals 2020; 13(6): 111.
[http://dx.doi.org/10.3390/ph13060111] [PMID: 32485996]
[29]
Dunga AK, Allaka TR, Kethavarapu Y, et al. Design, synthesis and biological evaluation of novel substituted indazole-1,2,3-triazolyl-1,3,4-oxadiazoles: Antimicrobial activity evaluation and docking study. Results Chem 2022; 4: 100605.
[http://dx.doi.org/10.1016/j.rechem.2022.100605]
[30]
Gogisetti G, Kanna U, Sharma V, Allaka RT, Tadiboina RB. Design, synthesis and bio-evaluation of novel chalcones bridged with 1,3,4-oxadiazole linkers: ADMET and docking analysis. Chem Biodivers 2022; 19(12): e202200681.
[http://dx.doi.org/10.1002/cbdv.202200681] [PMID: 36417552]
[31]
Deng Y, Yin S, Jing X, Zheng Y. Design, synthesis, and antiviral activities evaluation of novel quinazoline derivatives containing sulfonamide moiety. Heterocycl Commun 2023; 29(1): 20220160.
[http://dx.doi.org/10.1515/hc-2022-0160]
[32]
Allaka TR, Kummari B, Polkam N, Kuntala N, Chepuri K, Anireddy JS. Novel heterocyclic 1,3,4-oxadiazole derivatives of fluoroquinolones as a potent antibacterial agent: Synthesis and computational molecular modeling. Mol Divers 2022; 26(3): 1581-96.
[http://dx.doi.org/10.1007/s11030-021-10287-3] [PMID: 34341943]
[33]
Al-Rashood ST, Hamed AR, Hassan GS, et al. Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity. J Enzyme Inhib Med Chem 2020; 35(1): 831-9.
[http://dx.doi.org/10.1080/14756366.2020.1743281] [PMID: 32208781]
[34]
Thabrew MI, Hughes RD, McFarlane IG. Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J Pharm Pharmacol 2011; 49(11): 1132-5.
[http://dx.doi.org/10.1111/j.2042-7158.1997.tb06055.x] [PMID: 9401951]
[35]
Ibrahim MK, Abd-Elrahman AA, Ayyad RRA, El-Adl K, Mansour AM, Eissa IH. Design and synthesis of some novel 2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)-N-(4-(substituted)phenyl)acetamide derivatives for biological evaluation as anticonvulsant agents. Bull Fac Pharm Cairo Univ 2013; 51(1): 101-11.
[http://dx.doi.org/10.1016/j.bfopcu.2012.11.003]
[36]
O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open babel: An open chemical toolbox. J Cheminform 2011; 3(1): 33.
[http://dx.doi.org/10.1186/1758-2946-3-33] [PMID: 21982300]
[37]
Wu CC, Li YC, Wang YR, Li TK, Chan NL. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs. Nucleic Acids Res 2013; 41(22): 10630-40.
[http://dx.doi.org/10.1093/nar/gkt828] [PMID: 24038465]
[38]
Rao VG, Allaka TR, Gandla MK, et al. Synthesis, antimicrobial activity, and in silico studies of fluoroquinolones bearing 1,3,4-oxadiazolyl-triazole derivatives. J Heterocycl Chem 2023; 60(10): 1666-83.
[http://dx.doi.org/10.1002/jhet.4700]
[39]
Khattab ESAEH, Ragab A, Ftouh AMA, Elhenawy AA. Therapeutic strategies for Covid-19 based on molecular docking and dynamic studies to the ACE-2 receptors, Furin, and viral spike proteins. J Biomol Struct Dyn 2022; 40(23): 13291-309.
[http://dx.doi.org/10.1080/07391102.2021.1989036] [PMID: 34647855]
[40]
Bakchi B, Krishna AD, Sreecharan E, et al. An overview on applications of SwissADME web tool in the design and development of anticancer, antitubercular and antimicrobial agents: A medicinal chemist’s perspective. J Mol Struct 2022; 1259: 132712.
[http://dx.doi.org/10.1016/j.molstruc.2022.132712]
[41]
Hassan AS, Morsy NM, Aboulthana WM, Ragab A. Exploring novel derivatives of isatin-based Schiff bases as multi-target agents: design, synthesis, in vitro biological evaluation, and in silico ADMET analysis with molecular modeling simulations. RSC Advances 2023; 13(14): 9281-303.
[http://dx.doi.org/10.1039/D3RA00297G] [PMID: 36950709]
[42]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(1-3): 3-26.
[http://dx.doi.org/10.1016/S0169-409X(00)00129-0] [PMID: 11259830]
[43]
Daina A, Zoete V. A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 2016; 11(11): 1117-21.
[http://dx.doi.org/10.1002/cmdc.201600182] [PMID: 27218427]

Rights & Permissions Print Cite
Article Metrics
8
1
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy